Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? We need to look for any statement in the transcript where management contrasts the size of current deals with past deals for the same kind of business, indicating escalation. Also, it must be already real and recurring, and early (i.e., not fully reflected in results yet). Let's scan the transcript. The call is about ReNew Energy, a renewable energy company in India. They discuss their portfolio, guidance, acquisitions, etc. Key points: They have 7 GW operating, up from 6.3 GW at Sept 30, 2021. They expect 8.2 GW by end of fiscal year. They talk about M&A opportunities, corporate PPAs, etc. But the question is specifically about whether the size of individual deals/contracts/projects is escalating. For example, are they signing larger PPAs now than before? Or larger acquisitions? Or larger projects? In the transcript, they mention acquisitions: "We have closed both of our recently announced acquisitions, a 99 megawatt hydro facility and a 260 megawatt solar project in Telangana." That's two acquisitions, but not necessarily indicating a trend of increasing size. They also mention "We have a significant amount of experience with M&A having acquired over 2 gigawatts in the last five years." That's total, not per deal. They talk about corporate PPA market: "We see a corporate PPA market in India of at least 25 gigawatts over the next few years." But that's market size, not deal size. They mention "We have already signed up about 100 megawatts worth of PPAs with corporate customers" - that's a total, not per deal. They talk about their target of 18 GW operational by FY25, but that's overall capacity. Is there any statement about the average size of new projects or contracts increasing? I don't see any explicit comparison.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.